[{"Assets_0_Q2_USD":354654000.0,"CommonStockSharesOutstanding_0_Q2_shares":19260000.0,"EarningsPerShareBasic_1_Q2_USD":0.65,"EarningsPerShareBasic_2_Q2_USD":1.27,"EarningsPerShareDiluted_1_Q2_USD":0.61,"EarningsPerShareDiluted_2_Q2_USD":1.2,"NetIncomeLoss_1_Q2_USD":12555000.0,"NetIncomeLoss_2_Q2_USD":24248000.0,"StockholdersEquity_0_Q2_USD":333402000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q2_shares":20601000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_2_Q2_shares":20256000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q2_shares":19206000.0,"WeightedAverageNumberOfSharesOutstandingBasic_2_Q2_shares":19167000.0,"Ticker":"ENTA","CIK":"1177648","name":"ENANTA PHARMACEUTICALS INC","OfficialName":"Enanta Pharmaceuticals Inc. Common Stock","form":"10-Q","period":"20180331","fy":"2018.0","fp":"Q2","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"1492537180.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: In Vitro & In Vivo Diagnostic Substances","Market":"NASDAQ","SP500":"nan","filed":"20180510"}]